procarbazine has been researched along with Glioma in 129 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 9.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 9.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 9.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 9.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 9.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 9.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 9.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 9.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 9.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 9.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 9.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 9.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 9.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 8.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 8.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 8.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 7.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 7.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 7.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 7.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 7.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 6.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "To evaluate tumor responses, event-free survival (EFS), overall survival (OS), and toxicity of chemotherapy, children with neurofibromatosis type 1 (NF1) and progressive low-grade glioma were enrolled into the Children's Oncology Group (COG) A9952 protocol and treated with carboplatin and vincristine (CV)." | 5.22 | Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group. ( Ater, JL; Booth, TN; Freyer, DR; Mazewski, CM; Packer, RJ; Pollack, IF; Sposto, R; Vezina, G; Xia, C, 2016) |
| "The purpose of this prospective phase II/III trial was to study the effect of therapy intensification when combining procarbazine, lomustine, and vincristine (PCV) chemotherapy with a standard course of radiation therapy (RT) on cognitive functioning for patients with World Health Organization grade 2 low-grade gliomas (LGGs)." | 5.19 | Patients with primary brain tumors. ( Behrend, SW, 2014) |
| "The addition of PCV (procarbazine, lomustine, and vincristine) chemotherapy to radiotherapy (RT) for patients with WHO grade 2 glioma improves progression-free survival (PFS)." | 5.19 | Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Gilbert, MR; Hu, C; Mehta, MP; Prabhu, RS; Shaw, EG; Stelzer, KJ; Won, M, 2014) |
| "Thalidomide and procarbazine have demonstrated single agent activity against malignant gliomas (MG)." | 5.16 | A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas. ( Case, D; Ellis, TL; Enevold, G; Lesser, GJ; McMullen, KP; McQuellon, RP; Rosdhal, R; Ruiz, J; Shaw, EG; Stieber, VW; Tatter, SB, 2012) |
| "A prior Radiation Therapy Oncology Group (RTOG) clinical trial in anaplastic oligodendroglioma suggested a progression-free survival benefit for procarbazine, lomustine, and vincristine (PCV) chemotherapy in addition to radiation therapy (RT), as have smaller trials in low-grade glioma (LGG)." | 5.16 | Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. ( Barger, GR; Brachman, DG; Brown, PD; Buckner, JC; Coons, SW; Gilbert, MR; Mehta, MP; Shaw, EG; Stelzer, KJ; Wang, M, 2012) |
| "Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)." | 5.14 | Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010) |
| "Procarbazine hydrochloride (PCB) is one of the few anticancer drugs with activity against high-grade gliomas." | 5.12 | The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. ( Alavi, JB; Batchelor, TT; Carson, KA; Fisher, JD; Grossman, SA; Hammour, T; Lesser, G; Mikkelsen, T; Phuphanich, S; Supko, JG, 2006) |
| "Temozolomide (TMZ) is an oral alkylating agent with a good safety profile and proven efficacy in the treatment of malignant glioma." | 5.10 | Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. ( Foster, T; Newlands, ES; Zaknoen, S, 2003) |
| "The aim of this study was to compare tolerance of a nitrosurea-based regime with 'standard' therapy of vincristine (VCR) and carboplatin for low-grade gliomas." | 5.10 | Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas. ( Hoddes, JA; Lancaster, DL; Michalski, A, 2003) |
| "The aims of this phase I study in patients with recurrent malignant gliomas were to determine the maximum tolerated dose (MTD) and toxicity profile of fotemustine when combined with a fixed dose of procarbazine (PCZ), and to evaluate the extent of O6-alkylguanine-DNA alkyltransferase (ATase) depletion in circulating lymphocytes during treatment." | 5.09 | Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity. ( Berger, E; Boiardi, A; Ciusani, E; Giroux, B; Lucas, C; Margison, G; Silvani, A; Watson, A, 2001) |
| " Between May 1992 and January 1998, eight children with unresectable or recurrent intramedullary glioma were treated with the BB SFOP protocol (a 16-month chemotherapy regimen with carboplatin, procarbazine, vincristine, cyclophosphamide, etoposide and cisplatin)." | 5.09 | Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). ( Chastagner, P; Chouffai, Z; Couanet, D; Doireau, V; Grignon, Y; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Marchal, JC; Zerah, M, 1999) |
| "This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas." | 5.08 | A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392). ( Adams, G; Flynn, P; Grunnet, M; Hellman, R; Karp, D; Neuberg, DS; Robins, HI; Wagner, H, 1998) |
| "Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma." | 5.08 | Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. ( Buckner, JC; Burch, PA; Dinapoli, RP; Galanis, E; Mailliard, JA; Morton, RF; Novotny, PJ; Rowland, KM; Schaefer, PL; Scheithauer, BW; Vukov, AM, 1998) |
| "The regimen of procarbazine, CCNU, and vincristine is active against gliomas." | 5.08 | Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas. ( Cornetta, K; Dropcho, E; Heilman, DK; Jakacki, RI; Jamison, C; Macdonald, DR; Mathews, VP; Williams, DA, 1998) |
| "Twenty patients previously treated with surgery, radiation therapy and chemotherapy with a nitrosourea for malignant supratentorial gliomas received a combination of procarbazine, thiotepa and vincristine (P." | 5.07 | Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study. ( Ameri, A; Chen, QM; Delattre, JY; Poisson, M, 1993) |
| "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of three chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin)." | 5.06 | Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA; VanGilder, JC, 1989) |
| "We undertook a phase II study of combination chemotherapy with mechlorethamine (nitrogen mustard) 6 mg/m2 intravenously day 1 and day 8, vincristine 2 mg intravenously day 1 and day 8, and procarbazine 100 mg/m2 orally days 1 through 14 (MOP) in adults with recurrent high-grade glioma." | 5.06 | Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study. ( Baptista, J; Clark, K; Coyle, T; Graziano, S; King, R; Kirshner, J; Newman-Palmer, N; Poiesz, B; Scalzo, A; Winfield, J, 1990) |
| " The protocol called for a randomized trial that compared the effects of following 60 Gy radiation/oral hydroxyurea treatment with either carmustine (BCNU) or the combination of procarbazine, lomustine (CCNU), and vincristine (PCV) for two histologic strata: glioblastoma multiforme and other anaplastic gliomas." | 5.06 | Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. ( Davis, RL; Gutin, PH; Hannigan, J; Levin, VA; Silver, P; Wara, WM; Wilson, CB, 1990) |
| "A controlled study of 226 age-matched patients with histologically proven grade 3 and 4 supratentorial gliomas with maximum feasible tumour resection, postoperative Karnofsky performance over 50 and minimum survival of 8 weeks compares the results of supportive care (45 cases), high-dose irradiation of 40 to 66 Gy (59 cases), COMP protocol (CCNU, procarbazine, vincristine, methotrexate, prednisone in 15 day cycles-42 cases) and simultaneous irradiation and COMP chemotherapy (80 cases including 30 survivors)." | 5.05 | [Combined treatment of malignant gliomas]. ( Flament, H; Grisold, W; Jellinger, K; Volc, D; Vollmer, R; Weiss, R, 1983) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "Within 3 weeks of definitive surgery, 609 patients with histologically demonstrated, supratentorial malignant glioma were randomized to receive, in addition to 6000 rads of radiotherapy, one of four treatment regimens: carmustine (BCNU), high-dose methylprednisolone, procarbazine, or BCNU plus high-dose methylprednisolone." | 5.05 | Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. ( Alexander, E; Batzdorf, U; Brooks, WH; Byar, DP; Green, SB; Hunt, WE; Mealey, J; Odom, GL; Paoletti, P; Pistenmaa, DA; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Smith, KR; Strike, TA; Walker, MD; Wilson, CB, 1983) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The long-term follow-up of the RTOG 9802 trial that compared 54 Gy of radiotherapy (RT) with the same RT followed by adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy in high-risk low-grade glioma shows a major increase in survival after adjuvant PCV chemotherapy." | 4.90 | Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma. ( van den Bent, MJ, 2014) |
| "The methylhydrazine derivative Procarbazine (PCZ) as monotherapy or in combination with CCNU and vincristine (PCV) was evaluated in a vast number of clinical trials and is still used in patients with high-grade and low-grade gliomas." | 4.84 | Procarbazine--a traditional drug in the treatment of malignant gliomas. ( Bogdahn, U; Goerne, R; Hau, P, 2008) |
| "We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma." | 4.80 | Acute leukemia following treatment of malignant glioma. ( Brown, MT; Gockerman, JP; Perry, JR, 1998) |
| "The authors report the clinical features of hypersensitivity reactions believed to result from procarbazine in eight patients treated with mechlorethamine, vincristine, and procarbazine (MOP) for high-grade glioma." | 4.78 | Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. ( Bushunow, P; Coyle, T; Graziano, S; Winfield, J; Wright, J, 1992) |
| "Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG)." | 4.02 | One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre. ( Aslam, R; Breathnach, OS; Coyne, Z; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Morris, PG, 2021) |
| "Systematic evaluation of the effectiveness and safety of combined procarbazine, lomustine, and vincristine for treating recurrent high-grade glioma." | 3.96 | A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis. ( Cai, Y; Jiang, YG; Jiang, ZH; Tan, ZG; Wang, M, 2020) |
| " However, a randomized controlled study (RTOG 9802) showed that adding of procarbazine, CCNU, and vincristine (PCV) chemotherapy to fractionated radiotherapy (FRT) in patients with "high-risk" WHO grade II gliomas, including DA, has significant positive impact on both progression-free survival and overall survival." | 3.88 | Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults. ( Narita, Y, 2018) |
| "The addition of procarbazine, lomustine, vincristine (PCV) chemotherapy to radiotherapy (RT) for patients with high-risk (≥40 y old or subtotally resected) low-grade glioma (LGG) results in an absolute median survival benefit of over 5 years." | 3.85 | Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma. ( Bendavid, E; Chang, DT; Chin, AL; Durkee, BY; Harris, JP; Kim, H; Kumar, KA; Maruyama, S; Owens, DK; Pitt, A; Pollom, EL; Qian, Y; Soltys, SG, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 3.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "We previously developed a mathematical model capturing tumor size dynamics of adult low-grade gliomas (LGGs) before and after treatment either with PCV (Procarbazine, CCNU, and Vincristine) chemotherapy alone or with radiotherapy (RT) alone." | 3.81 | Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation. ( Ducray, F; Honnorat, J; Mazzocco, P; Ribba, B, 2015) |
| "We have studied the effects of medroxyprogesterone acetate (MPA) on C6 glioma growth in vitro in order to prove the hypothesis that it could arrest growth and induce drug sensitisation in a glial tumour as it does in breast cancer cells." | 3.71 | Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro. ( Altinoz, MA; Bilir, A; Onar, FD; Ozar, E; Sav, A, 2001) |
| "Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas." | 3.69 | [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. ( Bouffet, E; Bret, P; Helfre, S; Jouvet, A; Mertens, P; Mornex, F; Sindou, M; Thiesse, P, 1997) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with gliomas [grade IV (10), grade III (15), grade II (6)]." | 3.68 | Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas. ( Bromberg, J; Greenberg, HS; Junck, L; Newton, HB; Page, MA, 1993) |
| "We used human anaplastic glioma xenografts to evaluate the therapeutic efficacy of combinations of alkylating drugs, either 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2-chloroethyl)-3-(2,5-dioxo-3-piperidyl)-1-nitrosourea (PCNU), or procarbazine, and thiopurines, either 6-mercaptopurine (6MP) or 6-thioguanine (6TG)." | 3.68 | Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. ( Bigner, DD; Bodell, WJ; Elion, GB; Friedman, HS; Schold, SC; Wang, AM, 1991) |
| "Twenty-six patients with intracerebral tumors (predominantly gliomas) were treated with intraarterial BCNU, VM-26, and cisplatin combined with the systemic administration of VM-26, methotrexate, vincristine, bleomycin, and procarbazine." | 3.67 | Combined intraarterial and systemic chemotherapy for intracerebral tumors. ( Benoit, B; Grahovac, Z; Hugenholtz, H; Richard, M; Russell, N; Stewart, DJ, 1987) |
| "One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following whole head irradiation." | 3.67 | Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma. ( Bozek, T; Capra, LG; Collins, CD; Darling, JL; Godlee, JN; Mooney, C; Mott, TJ; Paul, EA; Thomas, DG; Tobias, JS, 1985) |
| "Intracerebral murine glioma 26 was used as a model system for evaluating two-drug combinations of antitumor agents, BCNU was combined with either procarbazine, dianhydrogalactitol, or ellipticine." | 3.66 | Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens. ( Levin, VA; Wilson, CB, 1978) |
| "A human medulloblastoma (BN-2) and a glioblastoma (BN-3) which were previously established in nude mice were used to determine the effect of combined modality therapy with gamma-radiation, and three chemotherapeutic agents, procarbazine, 1,4-cyclohexadiene-1,4-dicarbamic acid, 2,5-bis(1-aziridinyl)-3,6-dioxo diethylester (AZQ), and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.66 | Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model. ( Feola, J; Houchens, DP; Ovejera, AA; Slagel, DE, 1982) |
| "Intrinsic subtypes are highly prognostic in EORTC 26951 and improve outcome prediction when combined with other prognostic factors." | 2.78 | Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu ( de Rooi, J; den Dunnen, WF; Eilers, PH; Erdem-Eraslan, L; French, PJ; Gorlia, T; Gravendeel, LA; Idbaih, A; Kros, JM; Sillevis Smitt, PA; Spliet, WG; Teepen, JL; van den Bent, MJ; Wesseling, P, 2013) |
| "Those treated for glioblastoma multiforme had a mean Karnofsky Performance Score of 86% (range 60-100%) at 1 month and 75% (range 60-100%) at 24 months." | 2.67 | External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. ( Gutin, PH; Larson, DA; Leibel, SA; Levin, VA; Phillips, TL; Prados, MD; Silver, P; Sneed, PK; Wara, WM; Weaver, KA, 1991) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| " On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow." | 2.64 | [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. ( Buge, A; Poisson, M; Pouillart, P, 1978) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| "Procarbazine was not given as a specified protocol, but for patients who were ineligible or refused other protocols." | 2.38 | Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. ( Levin, VA; Prados, M; Rodriguez, LA; Silver, P, 1989) |
| "Of the 13 children with a residual tumour, chemotherapy induced 2 partial responses (PR), 1 minor response (MR) and 1 stable disease (SD) with no recurrent disease." | 1.33 | High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. ( Chastagner, P; Doz, F; Dufour, C; Frappaz, D; Gentet, JC; Grill, J; Kalifa, C; Lellouch-Tubiana, A; Pichon, F; Plantaz, D; Puget, S; Raquin, MA, 2006) |
| "Procarbazine is a cytotoxic chemotherapeutic agent used in the treatment of lymphomas and brain tumors." | 1.32 | Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry. ( Batchelor, TT; Grossman, S; He, X; Supko, JG, 2004) |
| " Toxic effects resulted when procarbazine, a drug of this class, was used in treating a child with a CNS tumor." | 1.28 | Monoamine oxidase inhibitor toxicity. ( Pack, R; Pfefferbaum, B; van Eys, J, 1989) |
| "Secondary acute leukemias are rare in the evolution of malignant gliomas and the usefulness of subsequent radiochemotherapy cannot be questioned at the present time." | 1.27 | Two cases of acute leukemia following treatment of malignant glioma. ( Audebert, AA; Canuel, C; Debray, J; Genot, JY; Krulik, M; Poisson, M; Renoux, M; Smadja, N; van Efferterre, R, 1983) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| " BCNU in combination with Vincristine and Procarbazine every 6 weeks." | 1.27 | Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors. ( Balsys, R; Bremer, AM; Duarte, P; Gonzalez, N; Kleriga, E; Miller, RI; Nguyen, TQ; Northup, HM, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (34.11) | 18.7374 |
| 1990's | 28 (21.71) | 18.2507 |
| 2000's | 25 (19.38) | 29.6817 |
| 2010's | 26 (20.16) | 24.3611 |
| 2020's | 6 (4.65) | 2.80 |
| Authors | Studies |
|---|---|
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Van der Valk, H | 1 |
| Dijkstra, H | 2 |
| Walenkamp, A | 1 |
| Schuttelaar, MLA | 1 |
| Oude Elberink, HNG | 2 |
| Van de Ven, AAJM | 2 |
| Raswoli, M | 1 |
| Nobre, L | 1 |
| Hawkins, C | 2 |
| Bartels, UK | 1 |
| Tabori, U | 2 |
| Bouffet, E | 3 |
| Cai, Y | 1 |
| Jiang, YG | 1 |
| Wang, M | 2 |
| Jiang, ZH | 1 |
| Tan, ZG | 1 |
| Keogh, RJ | 1 |
| Aslam, R | 1 |
| Hennessy, MA | 1 |
| Coyne, Z | 1 |
| Hennessy, BT | 1 |
| Breathnach, OS | 1 |
| Grogan, L | 1 |
| Morris, PG | 1 |
| Hutten, EM | 1 |
| Lambeck, AJA | 1 |
| Nuver, J | 1 |
| Qian, Y | 1 |
| Maruyama, S | 1 |
| Kim, H | 1 |
| Pollom, EL | 1 |
| Kumar, KA | 1 |
| Chin, AL | 1 |
| Harris, JP | 1 |
| Chang, DT | 1 |
| Pitt, A | 1 |
| Bendavid, E | 1 |
| Owens, DK | 1 |
| Durkee, BY | 1 |
| Soltys, SG | 1 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Narita, Y | 1 |
| Wick, W | 2 |
| Winkler, F | 1 |
| Prabhu, RS | 1 |
| Won, M | 1 |
| Shaw, EG | 3 |
| Hu, C | 1 |
| Brachman, DG | 2 |
| Buckner, JC | 3 |
| Stelzer, KJ | 2 |
| Barger, GR | 2 |
| Brown, PD | 2 |
| Gilbert, MR | 2 |
| Mehta, MP | 2 |
| Behrend, SW | 1 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| van den Bent, MJ | 3 |
| Schiff, D | 1 |
| Levin, VA | 17 |
| Rinne, ML | 1 |
| Wen, PY | 1 |
| Brandes, AA | 1 |
| Bartolotti, M | 1 |
| Tosoni, A | 1 |
| Franceschi, E | 1 |
| Mazzocco, P | 2 |
| Honnorat, J | 3 |
| Ducray, F | 5 |
| Ribba, B | 1 |
| Ater, JL | 2 |
| Xia, C | 1 |
| Mazewski, CM | 2 |
| Booth, TN | 2 |
| Freyer, DR | 2 |
| Packer, RJ | 2 |
| Sposto, R | 2 |
| Vezina, G | 2 |
| Pollack, IF | 2 |
| Ollier, E | 1 |
| Ricard, D | 2 |
| Kaloshi, G | 1 |
| Idbaih, A | 2 |
| Alentorn, A | 1 |
| Psimaras, D | 1 |
| Delattre, JY | 2 |
| Grenier, E | 1 |
| Samson, A | 1 |
| Goerne, R | 1 |
| Bogdahn, U | 1 |
| Hau, P | 1 |
| Huang, F | 1 |
| Kavan, P | 1 |
| Guiot, MC | 1 |
| Markovic, Y | 1 |
| Roberge, D | 1 |
| Ashley, DM | 1 |
| Riffkin, CD | 1 |
| Lovric, MM | 1 |
| Mikeska, T | 1 |
| Dobrovic, A | 1 |
| Maxwell, JA | 1 |
| Friedman, HS | 5 |
| Drummond, KJ | 1 |
| Kaye, AH | 1 |
| Gan, HK | 1 |
| Johns, TG | 1 |
| Hawkins, CJ | 1 |
| Baumert, BG | 1 |
| Stupp, R | 1 |
| DeAngelis, LM | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Felsberg, J | 1 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 1 |
| Meyermann, R | 1 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 1 |
| Pietsch, T | 1 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 1 |
| Reifenberger, G | 1 |
| von Deimling, A | 1 |
| Weller, M | 1 |
| Mishra, KK | 1 |
| Squire, S | 1 |
| Lamborn, K | 3 |
| Banerjee, A | 1 |
| Gupta, N | 1 |
| Wara, WM | 5 |
| Prados, MD | 6 |
| Berger, MS | 1 |
| Haas-Kogan, DA | 1 |
| Agha, CA | 1 |
| Ibrahim, S | 1 |
| Hassan, A | 1 |
| Elias, DA | 1 |
| Fathallah-Shaykh, HM | 1 |
| Peyre, M | 1 |
| Cartalat-Carel, S | 1 |
| Meyronet, D | 1 |
| Jouvet, A | 3 |
| Pallud, J | 1 |
| Mokhtari, K | 1 |
| Guyotat, J | 2 |
| Jouanneau, E | 2 |
| Sunyach, MP | 2 |
| Frappaz, D | 3 |
| Brada, M | 1 |
| Stenning, S | 1 |
| Gabe, R | 1 |
| Thompson, LC | 1 |
| Levy, D | 1 |
| Rampling, R | 1 |
| Erridge, S | 1 |
| Saran, F | 1 |
| Gattamaneni, R | 1 |
| Hopkins, K | 1 |
| Beall, S | 1 |
| Collins, VP | 1 |
| Lee, SM | 1 |
| Scheinemann, K | 1 |
| Bartels, U | 1 |
| Tsangaris, E | 1 |
| Huang, A | 1 |
| Dirks, P | 1 |
| Fried, I | 1 |
| Ruiz, J | 1 |
| Case, D | 1 |
| Enevold, G | 1 |
| Rosdhal, R | 1 |
| Tatter, SB | 1 |
| Ellis, TL | 1 |
| McQuellon, RP | 1 |
| McMullen, KP | 1 |
| Stieber, VW | 1 |
| Lesser, GJ | 1 |
| Zhou, T | 1 |
| Holmes, E | 2 |
| Lazarus, KH | 1 |
| Prados, M | 2 |
| Wisoff, JH | 1 |
| Coons, SW | 1 |
| Viaccoz, A | 1 |
| Lekoubou, A | 1 |
| Erdem-Eraslan, L | 1 |
| Gravendeel, LA | 1 |
| de Rooi, J | 1 |
| Eilers, PH | 1 |
| Spliet, WG | 1 |
| den Dunnen, WF | 1 |
| Teepen, JL | 1 |
| Wesseling, P | 1 |
| Sillevis Smitt, PA | 2 |
| Kros, JM | 1 |
| Gorlia, T | 1 |
| French, PJ | 1 |
| Baker, MJ | 1 |
| Brem, S | 1 |
| Daniels, S | 1 |
| Sherman, B | 1 |
| Phuphanich, S | 2 |
| Vos, MJ | 1 |
| Uitdehaag, BM | 1 |
| Barkhof, F | 1 |
| Heimans, JJ | 2 |
| Baayen, HC | 1 |
| Boogerd, W | 1 |
| Castelijns, JA | 1 |
| Elkhuizen, PH | 1 |
| Postma, TJ | 2 |
| Pommier, P | 1 |
| Martel Lafay, I | 1 |
| Ginestet, G | 1 |
| Sindou, M | 2 |
| Bret, P | 2 |
| Carrie, C | 1 |
| Ogawa, K | 2 |
| Yoshii, Y | 2 |
| Inoue, O | 2 |
| Toita, T | 2 |
| Saito, A | 2 |
| Kakinohana, Y | 2 |
| Adachi, G | 2 |
| Ishikawa, Y | 1 |
| Kin, S | 1 |
| Murayama, S | 2 |
| Newlands, ES | 1 |
| Foster, T | 1 |
| Zaknoen, S | 1 |
| Lancaster, DL | 1 |
| Hoddes, JA | 1 |
| Michalski, A | 1 |
| He, X | 1 |
| Batchelor, TT | 2 |
| Grossman, S | 1 |
| Supko, JG | 2 |
| de Wit, MC | 1 |
| de Bruin, HG | 1 |
| Eijkenboom, W | 1 |
| Neyns, B | 1 |
| Sadones, J | 1 |
| Chaskis, C | 1 |
| De Ridder, M | 1 |
| Keyaerts, M | 1 |
| Veld, PI | 1 |
| Michotte, A | 1 |
| Chintagumpala, MM | 1 |
| Stewart, CF | 1 |
| Kepner, J | 1 |
| McLendon, RE | 1 |
| Modrich, PL | 1 |
| McCluggage, C | 1 |
| Burger, P | 1 |
| Thompson, S | 1 |
| Rutka, J | 1 |
| Michalski, J | 1 |
| Woo, S | 1 |
| Blaney, SM | 1 |
| Kun, LE | 1 |
| Horowitz, ME | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Lesser, G | 1 |
| Mikkelsen, T | 1 |
| Alavi, JB | 1 |
| Hammour, T | 1 |
| Fisher, JD | 1 |
| Iraha, S | 1 |
| Tamaki, W | 1 |
| Sugimoto, K | 1 |
| Hyodo, A | 1 |
| Dufour, C | 1 |
| Grill, J | 2 |
| Lellouch-Tubiana, A | 2 |
| Puget, S | 1 |
| Chastagner, P | 3 |
| Doz, F | 1 |
| Pichon, F | 1 |
| Plantaz, D | 1 |
| Gentet, JC | 1 |
| Raquin, MA | 1 |
| Kalifa, C | 2 |
| Yang, SH | 1 |
| Hong, YK | 1 |
| Yoon, SC | 1 |
| Kim, BS | 1 |
| Lee, YS | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kim, MC | 1 |
| Park, CK | 1 |
| Neuwelt, EA | 1 |
| Hill, SA | 1 |
| Frenkel, EP | 1 |
| Schold, SC | 5 |
| Bigner, DD | 4 |
| West, CR | 1 |
| Avellanosa, AM | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Green, SB | 2 |
| Byar, DP | 1 |
| Walker, MD | 1 |
| Pistenmaa, DA | 1 |
| Alexander, E | 1 |
| Batzdorf, U | 1 |
| Brooks, WH | 1 |
| Hunt, WE | 1 |
| Mealey, J | 2 |
| Odom, GL | 1 |
| Paoletti, P | 1 |
| Ransohoff, J | 2 |
| Robertson, JT | 2 |
| Selker, RG | 2 |
| Shapiro, WR | 6 |
| Smith, KR | 1 |
| Wilson, CB | 11 |
| Strike, TA | 2 |
| Bremer, AM | 1 |
| Kleriga, E | 1 |
| Nguyen, TQ | 1 |
| Balsys, R | 1 |
| Northup, HM | 1 |
| Gonzalez, N | 1 |
| Duarte, P | 1 |
| Miller, RI | 1 |
| Jellinger, K | 2 |
| Volc, D | 2 |
| Grisold, W | 2 |
| Flament, H | 2 |
| Vollmer, R | 2 |
| Weiss, R | 2 |
| Rawlings, CE | 1 |
| Bigner, SH | 1 |
| Genot, JY | 1 |
| Krulik, M | 1 |
| Poisson, M | 4 |
| van Efferterre, R | 1 |
| Renoux, M | 1 |
| Audebert, AA | 1 |
| Canuel, C | 1 |
| Smadja, N | 1 |
| Debray, J | 1 |
| Vestnys, PS | 1 |
| Slagel, DE | 1 |
| Feola, J | 1 |
| Houchens, DP | 1 |
| Ovejera, AA | 1 |
| Podreka, I | 1 |
| Yung, WA | 1 |
| Basler, GA | 1 |
| Shapiro, JR | 2 |
| Jeremic, B | 2 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Stojanovic, M | 1 |
| Shibamoto, Y | 1 |
| Cairncross, JG | 3 |
| Ameri, A | 1 |
| Chen, QM | 1 |
| Watne, K | 1 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 1 |
| Hirschberg, H | 1 |
| Newton, HB | 1 |
| Bromberg, J | 1 |
| Junck, L | 1 |
| Page, MA | 1 |
| Greenberg, HS | 1 |
| Forsyth, PA | 1 |
| Haselsberger, K | 1 |
| Peterson, DC | 1 |
| Thomas, DG | 3 |
| Darling, JL | 4 |
| Kyritsis, AP | 2 |
| Yung, WK | 2 |
| Jaeckle, KA | 2 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Edwards, MS | 1 |
| Rabbitt, J | 2 |
| Davis, RL | 3 |
| Mornex, F | 1 |
| Thiesse, P | 1 |
| Mertens, P | 1 |
| Helfre, S | 1 |
| Hellman, R | 1 |
| Neuberg, DS | 1 |
| Wagner, H | 1 |
| Grunnet, M | 1 |
| Robins, HI | 1 |
| Karp, D | 1 |
| Flynn, P | 1 |
| Adams, G | 1 |
| van Groeningen, CJ | 1 |
| Witjes, RJ | 1 |
| Weerts, JG | 1 |
| Kralendonk, JH | 1 |
| Galanis, E | 1 |
| Burch, PA | 1 |
| Schaefer, PL | 1 |
| Dinapoli, RP | 1 |
| Novotny, PJ | 1 |
| Scheithauer, BW | 1 |
| Rowland, KM | 1 |
| Vukov, AM | 1 |
| Mailliard, JA | 1 |
| Morton, RF | 1 |
| Jakacki, RI | 2 |
| Jamison, C | 2 |
| Mathews, VP | 1 |
| Heilman, DK | 1 |
| Dropcho, E | 1 |
| Cornetta, K | 1 |
| Macdonald, DR | 1 |
| Williams, DA | 1 |
| Perry, JR | 1 |
| Brown, MT | 1 |
| Gockerman, JP | 1 |
| Doireau, V | 1 |
| Zerah, M | 1 |
| Couanet, D | 1 |
| Marchal, JC | 1 |
| Grignon, Y | 1 |
| Chouffai, Z | 1 |
| Siffert, J | 1 |
| Velasquez, L | 1 |
| Allen, JC | 1 |
| Bauman, GS | 1 |
| Wara, W | 1 |
| Davis, R | 1 |
| Edwards, M | 1 |
| Malec, M | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Ciusani, E | 1 |
| Watson, A | 1 |
| Margison, G | 1 |
| Berger, E | 1 |
| Lucas, C | 1 |
| Giroux, B | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Altinoz, MA | 1 |
| Bilir, A | 1 |
| Ozar, E | 1 |
| Onar, FD | 1 |
| Sav, A | 1 |
| Kochi, M | 1 |
| Ushio, Y | 1 |
| Crafts, DC | 1 |
| Schultz, MJ | 1 |
| Boldrey, EB | 4 |
| Enot, KJ | 3 |
| Pischer, TL | 2 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Gutin, P | 1 |
| Drafts, D | 1 |
| Ertel, IJ | 1 |
| Boesel, C | 1 |
| Heiss, WD | 1 |
| Turnheim, M | 1 |
| Mamoli, B | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Buge, A | 2 |
| Pouillart, P | 2 |
| Palangie, T | 1 |
| Huguenin, P | 1 |
| Morin, P | 1 |
| Gautier, H | 1 |
| Young, DF | 1 |
| Jovanovic, D | 1 |
| Djuric, LJ | 1 |
| Jevremovic, S | 1 |
| Mijatovic, LJ | 1 |
| Sneed, PK | 2 |
| Gutin, PH | 4 |
| Phillips, TL | 2 |
| Weaver, KA | 2 |
| Larson, DA | 2 |
| Gumerlock, MK | 1 |
| Belshe, BD | 1 |
| Madsen, R | 1 |
| Watts, C | 1 |
| Coyle, T | 2 |
| Bushunow, P | 1 |
| Winfield, J | 2 |
| Wright, J | 1 |
| Graziano, S | 2 |
| Leibel, SA | 1 |
| Silver, P | 3 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 1 |
| Gattamaneni, HR | 1 |
| Wang, AM | 1 |
| Elion, GB | 1 |
| Bodell, WJ | 1 |
| Hannigan, J | 1 |
| Baptista, J | 1 |
| Clark, K | 1 |
| Poiesz, B | 1 |
| Kirshner, J | 1 |
| Scalzo, A | 1 |
| Newman-Palmer, N | 1 |
| King, R | 1 |
| Bradford, R | 1 |
| Sier, N | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Hugenholtz, H | 1 |
| Russell, N | 1 |
| Richard, M | 1 |
| Benoit, B | 1 |
| Rodriguez, LA | 1 |
| Burger, PC | 1 |
| Mahaley, MS | 2 |
| VanGilder, JC | 1 |
| Djang, WT | 1 |
| Kurtzberg, J | 1 |
| Longee, DC | 1 |
| Halperin, EC | 1 |
| Falletta, JM | 1 |
| Coleman, RE | 1 |
| Oakes, WJ | 1 |
| Pfefferbaum, B | 1 |
| Pack, R | 1 |
| van Eys, J | 3 |
| Brent, TP | 1 |
| von Hofe, E | 1 |
| Mitra, S | 1 |
| Swenberg, JA | 1 |
| Kleihues, P | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vestnys, P | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Takaue, Y | 1 |
| Sullivan, MP | 1 |
| Ramirez, I | 1 |
| Cleary, KR | 1 |
| Albers, GW | 1 |
| Hoyt, WF | 1 |
| Forno, LS | 1 |
| Shratter, LA | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Baram, TZ | 1 |
| Cangir, A | 1 |
| Bruner, JM | 1 |
| Martinez-Prieto, J | 1 |
| Whaley, RA | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 1 |
| Cush, S | 1 |
| Afra, D | 1 |
| Kocsis, B | 1 |
| Kerpel-Fronius, S | 1 |
| Eckhardt, S | 1 |
| Paul, EA | 1 |
| Mott, TJ | 1 |
| Godlee, JN | 1 |
| Tobias, JS | 1 |
| Capra, LG | 1 |
| Collins, CD | 1 |
| Mooney, C | 1 |
| Bozek, T | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Vasantha Kumar, AR | 1 |
| Renaudin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma[NCT00003375] | Phase 2/Phase 3 | 370 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)[NCT05555550] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455] | Phase 3 | 500 participants (Anticipated) | Interventional | 2002-10-31 | Completed | ||
| Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old[NCT00002944] | Phase 3 | 428 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| A Phase II Randomized Sham-Controlled Trial With Allocation Concealment and Blinded Patients and Assessors, Investigating Hyperbaric Oxygen as a Radiation Sensitizer for Locally Advanced Squamous Cell Carcinoma of the Oropharynx and Larynx[NCT03843671] | Phase 2 | 400 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| A Phase I/II Study of Oral Procarbazine in the Treatment of Recurrent High Grade Astrocytomas[NCT00004004] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-07-31 | Completed | ||
| A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme[NCT00088400] | Phase 3 | 30 participants | Interventional | 2004-07-31 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
22 reviews available for procarbazine and Glioma
| Article | Year |
|---|---|
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
Practice changing mature results of RTOG study 9802: another positive PCV trial makes adjuvant chemotherapy part of standard of care in low-grade glioma.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase III as T | 2014 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Nitrosoureas in the Management of Malignant Gliomas.
Topics: Dacarbazine; Glioma; Humans; Lomustine; Nitrosourea Compounds; Organophosphorus Compounds; Procarbaz | 2016 |
Procarbazine--a traditional drug in the treatment of malignant gliomas.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cli | 2008 |
Chemotherapy for diffuse low-grade gliomas in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Chemother | 2011 |
Chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Clinical Trials | 2012 |
Conformal irradiation for pure and mixed oligodendroglioma: the experience of Centre Leon Berard Lyon.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Damage, Chronic; Brain Injuries | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Glioma; Humans; Proca | 2005 |
Aggressive oligodendroglioma: a chemosensitive tumor.
Topics: Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Ad | 1994 |
Chemotherapy for malignant gliomas.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, D | 1996 |
Acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Fatal Outcome | 1998 |
Multidisciplinary management of adult anaplastic oligodendrogliomas and anaplastic mixed oligo-astrocytomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; G | 2001 |
[Chemo-radiotherapy for malignant brain tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Central Nervous System | 2002 |
Chemotherapy: the agents in current use.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; Drug Therapy, Combination; Glioma; | 1975 |
Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Drug Hypersensit | 1992 |
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Child; Child, Preschool; Female; Glioblastoma; Glioma; Hum | 1989 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
41 trials available for procarbazine and Glioma
| Article | Year |
|---|---|
Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2014 |
Patients with primary brain tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Che | 2014 |
Nonrandomized comparison of neurofibromatosis type 1 and non-neurofibromatosis type 1 children who received carboplatin and vincristine for progressive low-grade glioma: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Child, Preschoo | 2016 |
When temozolomide alone fails: adding procarbazine in salvage therapy of glioma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Female; Glioma; Humans; Magnetic R | 2008 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Di | 2010 |
Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chi-Square | 2010 |
Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Di | 2011 |
A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Brain Neoplasms; Female; Follow-Up Studies; G | 2012 |
Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Central Nervous System | 2012 |
Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2012 |
Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2013 |
Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 2003 |
Tolerance of nitrosurea-based multiagent chemotherapy regime for low-grade pediatric gliomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Chi | 2003 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Alkyl and Aryl Transferases; Antineoplastic | 2006 |
The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Antineoplastic Agents; Cohort Studies; Disease P | 2006 |
Phase II trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Ther | 2006 |
Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Administration | 1983 |
[Combined treatment of malignant gliomas].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Drug Therapy, Com | 1983 |
Evaluation of CCNU, VM-26 plus CCNU, and procarbazine in supratentorial brain gliomas. Final evaluation of a randomized study. European Organization for Research on Treatment of Cancer (EORTC) Brain Tumor Group.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Drug Therapy, Combination; Female; | 1981 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combi | 1994 |
Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Glioma; Humans; Male; Middle Ag | 1993 |
Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 1997 |
A therapeutic trial of radiation therapy with Vincristine, etoposide, and Procarbazine (VVP) in high grade intracranial gliomas--an Eastern Cooperative Oncology Group Study (E2392).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Comb | 1998 |
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Female; Glioma; | 1998 |
Dose-intensification of procarbazine, CCNU (lomustine), vincristine (PCV) with peripheral blood stem cell support in young patients with gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1998 |
Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carboplatin; Chemotherapy, Adjuvant; Ch | 1999 |
Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 2000 |
Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Lymphocytes; Male; Midd | 2001 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
[A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)].
Topics: Adult; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Follow-Up | 1978 |
Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1992 |
External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Combine | 1991 |
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 1990 |
Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; G | 1990 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
67 other studies available for procarbazine and Glioma
| Article | Year |
|---|---|
Successful oral desensitization and reintroduction in selected glioma patients with procarbazine-mediated hypersensitivity.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Glioma; Humans; Procarbazine | 2020 |
Salvage chemotherapy after failure of targeted therapy in a child with BRAF V600E low-grade glioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child, Preschool; Glioma; Humans; L | 2021 |
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; | 2020 |
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug-Related Side Effects an | 2021 |
Successful rapid desensitization in a glioma patient with procarbazine-mediated anaphylaxis.
Topics: Anaphylaxis; Basophils; Desensitization, Immunologic; Glioma; Humans; Procarbazine | 2021 |
Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Cost-Bene | 2017 |
Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Topics: Adult; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Glioma; Humans; Procarbazi | 2018 |
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2015 |
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2015 |
Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Clinical Protocols; Clinical | 2015 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytes; Carb | 2008 |
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2008 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Bevacizumab is active as a single agent against recurrent malignant gliomas.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Glioma; Humans; Lomustine; | 2010 |
Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Femal | 2002 |
Interobserver variability in the radiological assessment of response to chemotherapy in glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat | 2003 |
Prospective trial of radiotherapy after hyperbaric oxygenation with chemotherapy for high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Glio | 2003 |
Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials, Phase | 2004 |
High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child, Preschool; Cisp | 2006 |
Radiotherapy plus concurrent and adjuvant procarbazine, lomustine, and vincristine chemotherapy for patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemothera | 2007 |
Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; B | 1984 |
Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin.
Topics: Animals; Carmustine; Disease Models, Animal; Drug Therapy, Combination; Glioma; Humans; Mice; Mice, | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Complications associated with intra-arterial BCNU administered in combination with vincristine and procarbazine for the treatment of malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum.
Topics: Animals; Antineoplastic Agents; Aziridines; Azirines; Benzoquinones; Brain Neoplasms; Carmustine; Ce | 1983 |
Two cases of acute leukemia following treatment of malignant glioma.
Topics: Acute Disease; Adult; Astrocytoma; Brain Neoplasms; Female; Glioma; Humans; Leukemia; Nitrosourea Co | 1983 |
Combined modality treatment using radiation and/or chemotherapy in an athymic nude mouse-human medulloblastoma and glioblastoma xenograft model.
Topics: Animals; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Cell Line; Glioma; Humans; Medullob | 1982 |
[Results of combined modality treatment of malignant gliomas. Comparison of postoperative irradiation, chemotherapy, and combined radio-polychemotherapy (author's transl)].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioma; Huma | 1981 |
Heterogeneous response to chemotherapy of human gliomas grown in nude mice and as clones in vitro.
Topics: Animals; Brain Neoplasms; Carmustine; Cell Line; Clone Cells; Glioma; Humans; Kinetics; Mice; Mice, | 1981 |
Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Ad | 1993 |
Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.
Topics: Adult; Brain Neoplasms; Carmustine; Female; Glioma; Humans; Male; Procarbazine | 1993 |
Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma.
Topics: Antineoplastic Agents; Coloring Agents; Drug Screening Assays, Antitumor; Glioma; Humans; Lomustine; | 1996 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Female; Gl | 1997 |
Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 1998 |
Dose-intensive, time-compressed procarbazine, CCNU, vincristine (PCV) with peripheral blood stem cell support and concurrent radiation in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Res | 1999 |
Medroxyprogesterone acetate alone or synergistic with chemotherapy suppresses colony formation and DNA synthesis in C6 glioma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Death; | 2001 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Brain tumors in children.
Topics: Adolescent; Astrocytoma; Brain; Brain Neoplasms; Child; Diagnosis, Differential; Ependymoma; Female; | 1978 |
Combination chemotherapy of malignant glioma. Effect of postoperative treatment with CCNU, vincristine, amethopterine and procarbazine.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Drug Therapy, Combination; Glioma; Humans; Lomustine; Meth | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Correlations between experimental chemotherapy in the murine glioma and effectiveness of clinical therapy regimens.
Topics: Animals; Carmustine; Dianhydrogalactitol; Drug Therapy, Combination; Ellipticines; Glioma; Lomustine | 1978 |
Treatment of adult malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Drug Therapy, Com | 1978 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride.
Topics: Brain Neoplasms; Drug Evaluation; Drug Therapy, Combination; Glioma; Humans; Lomustine; Nitrosourea | 1976 |
Chemotherapy of primary malignant brain tumors in children.
Topics: Antineoplastic Agents; Brain Neoplasms; Brain Stem; Carmustine; Child; Ependymoma; Glioma; Humans; M | 1975 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: patient series and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cyclophosphami | 1992 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts.
Topics: Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; DNA; Glioma; | 1991 |
The VM model of glioma: preparation of multicellular tumour spheroids (MTS) and their response to chemotherapy.
Topics: Animals; Carmustine; Cell Division; Disease Models, Animal; Drug Screening Assays, Antitumor; Glioma | 1990 |
Combined intraarterial and systemic chemotherapy for intracerebral tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain Neoplasms; | 1987 |
Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor.
Topics: Adolescent; Antineoplastic Agents; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Cohort S | 1989 |
Monoamine oxidase inhibitor toxicity.
Topics: Brain Neoplasms; Child; Female; Glioma; Humans; Procarbazine; Substance-Related Disorders | 1989 |
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.
Topics: Animals; Brain Neoplasms; Drug Resistance; Glioma; Humans; Medulloblastoma; Methyltransferases; Mice | 1989 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Second malignant neoplasm in treated Hodgkin's disease. Report of a patient and scope of the problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Combined Modality Therapy; G | 1986 |
Treatment response in malignant optic glioma of adulthood.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cranial Nerve Neoplasms; F | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Salvage chemotherapy for recurrent primary brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chi | 1988 |
Dibromodulcitol-based combined postoperative chemotherapy of malignant astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Combined | 1986 |
Assay of anti-cancer drugs in tissue culture: relationship of relapse free interval (RFI) and in vitro chemosensitivity in patients with malignant cerebral glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Female; Gli | 1985 |
Chemosensitivity testing in the treatment of malignant gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Glioma; Humans; Lomustine; Procarba | 1985 |
Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
Topics: Adolescent; Adult; Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Electroencephalography; Epe | 1974 |